English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Restasis® is the only ophthalmic medication containing cyclosporine A that is registered in the Russian Federation. According to prescribing information, it is indicated in keratoconjunctivitis sicca with decreased tear secretion. However, there are several similar conditions, in particular ophthalmic forms of graft versus host reaction, in which its use may be appropriate and of high practical interest. We observed 20 patients with ophthalmic forms of graft versus host reaction after bone marrow allografting. All patients were treated by Restasis® b.i.d., there were no side-effects. In one month of treatment tear breakup time test results improved, as well as the corneal epithelium status.

oftalʹmologičeskie vedomosti

Our experience of Restasis® use in patients with “dry eye” syndrome occurring against the context of graft versus host reaction after bone marrow allografting